Dr. Peter B. Corr
Co-Founder and Managing General Partner
Dr. Corr is Co-Founder and Managing General Partner of Auven Therapeutics. Dr. Corr retired from Pfizer Inc in December 2006 where he was Senior Vice President for Science and Technology. In 2002 and 2003, he also headed worldwide pharmaceutical research and development for Pfizer. Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development; and President, Worldwide Development. He also served as Senior Vice President, Discovery Research, at Monsanto/Searle and then, President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis. Dr. Corr, who received his doctorate from Georgetown University School of Medicine, spent 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis. When he left Washington University, Dr. Corr was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology. His research has been published in more than 160 scientific manuscripts. Dr. Corr is the recipient of numerous awards, including membership in the Alpha Omega Alpha National Medical Honorary Society, an Established Investigator Award from the American Heart Association, and a Research Career Development Award from the National Institutes of Health. He received the Washington University School of Medicine Teacher of the Year Award on several occasions and, in 1990, the Washington University Distinguished Faculty Award. In 2004, Dr. Corr was named a William Pitt Fellow at Pembroke College, Cambridge University, Cambridge, U.K. In addition to his work at Pfizer, Dr. Corr was Chairman of the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); Chairman of the PhRMA Foundation Board of Directors; and Chairman of the Hever Group, representing Chief Scientific Officers (CSO’s) across the European and U.S. based pharmaceutical industry. He is a past Governor of the New York Academy of Sciences (and past Chairman of the Board of Governors) and a member of the Board of Regents of Georgetown University. Additionally, he is Chairman of the Board of the International Partnership for Microbicides and Chairman of the Board of Directors of the Critical Path Institute, in Tucson, Arizona; and serves on the boards of Furiex Pharmaceuticals, Inc.; Global Edit, Inc.; and the African Leadership Congress. He is a member of the National Academies’ Institute of Medicine (IOM) Committee on Conflict of Interest in Medical Research, Education and Practice, the IOM Forum on Drug Discovery, Development and Translation and the IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development.